Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
Kei Yoshino, Tetsuya Hosooka, Masakazu Shinohara, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 557, pp. 62-68
Open Access | Times Cited: 13

Showing 13 citing articles:

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
Kaori Hozumi, Kenji Sugawara, Takaya Ishihara, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 31
Role of Oxylipins in the Inflammatory-Related Diseases NAFLD, Obesity, and Type 2 Diabetes
Mariya Misheva, Jethro S. Johnson, James McCullagh
Metabolites (2022) Vol. 12, Iss. 12, pp. 1238-1238
Open Access | Times Cited: 34
Maternal nutrient metabolism in the liver during pregnancy
Hongxu Fang, Qingyang Li, Haichao Wang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice
Jessica M. Snyder, Kerriann M. Casey, Andrzej T. Gałecki, et al.
GeroScience (2022) Vol. 45, Iss. 1, pp. 385-397
Open Access | Times Cited: 20
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease
Nami Lee, Yu Jung Heo, Sung‐E Choi, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 588, pp. 154-160
Open Access | Times Cited: 18
Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue
Shinichi Morita, Akira Sakamaki, Kyutaro Koyama, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Fatty Acids - From Biosynthesis to Human Health
Miroslav Blumenberg, Alicia Román‐Martínez, Erik Froyen, et al.
Biochemistry (2022)
Closed Access | Times Cited: 3
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Evangelia Makri, Eleftheria Makri, A. Goulas, et al.
Annals of Gastroenterology (2024)
Open Access
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
Husam M. Salah, Marat Fudim
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 625-634
Open Access | Times Cited: 2
Lipidomics as a Tool in the Diagnosis and Clinical Therapy
María Elizbeth Alvarez Sánchez, Erick Nolasco Ontiveros, Rodrigo Arreola, et al.
Biochemistry (2022)
Open Access | Times Cited: 1


Diabetes Obesity Metabolic Syndrome (2023), Iss. 5
Open Access
Page 1

Scroll to top